Atlas Trials

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Clinical trial NCT06680622 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06680622
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Gastro-esophageal Adenocarcinoma
Start date
2025-03-03
Primary completion
2027-09-01
Enrollment
126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.